|drug4387||azoximer bromide Wiki||1.00|
There is one clinical trial.
The primary aim of this study is to determine whether implementation of a postpartum patient navigation program improves health outcomes among low-income women. Patient navigation is a barrier focused, long-term patient-centered intervention that offers support for a defined set of health services. The intervention under investigation is a comprehensive postpartum patient navigator program. Women who are randomized to receive patient navigation will be compared to women who are randomized to receive usual care. Navigators will support women through one year postpartum. The NNM2 program will be grounded in understanding and addressing social determinants of health in order to promote self-efficacy, enhance access, and sustain long-term engagement. Participants will undergo surveys, interviews, and medical record review at 4-12 weeks and 11-13 months postpartum. The investigators will additionally conduct focus groups and surveys with clinical providers.
Description: Number of women who achieve a composite measure of health status that includes retention in care, receipt of recommended counseling (anticipatory guidance), receipt of desired contraception, postpartum depression screening and care, breastfeeding initiation and maintenance, and receipt of preventive care. (Outcome is modified to include receipt telemedicine for health care for women who require postpartum care during the pandemic)Measure: Postpartum health at 4-12 weeks after delivery Time: 4-12 weeks postpartum
Description: Among women with gestational diabetes mellitus (GDM), number of women with completion of a 2-hour oral glucose tolerance test by 12 weeks postpartumMeasure: Postpartum diabetes screening Time: 4-12 weeks and 1 year postpartum
Description: Among women with ASCVD-associated adverse pregnancy outcomes, number of women who undergo indicated clinical assessments for blood pressure, lipids, weight, nutrition, activityMeasure: Postpartum atherosclerotic cardiovascular disease screening Time: 4-12 weeks and 1 year postpartum
Description: Difference between weight at delivery and 1) weight at early postpartum (4-12 weeks) and 2) weight at 1 year postpartumMeasure: Gestational weight retention Time: 4-12 weeks and 1 year postpartum
Description: Total duration of exclusive or partial breastfeeding among women who desired breastfeedingMeasure: Breastfeeding Time: 4-12 weeks and 1 year postpartum
Description: Number of women with appointment made and kept for primary care by 1 year postpartumMeasure: Postpartum transition to primary care Time: 1 year postpartum
Description: Differences between self-efficacy, activation, and engagement between women who are randomized to navigation versus usual care, using the Department of Health and Human Services (DHHS) Patient-Reported Outcomes Measurement Information System.Measure: Patient-reported outcomes - self-efficacy, activation, and engagement Time: 4-12 weeks and 1 year postpartum
Description: Qualitative perspectives on experiences with the navigation program, based on interviews with women who received navigationMeasure: Experiences with navigation Time: 3-6 months postpartum and 1 year postpartum
Description: Qualitative perspective of participants' experiences during the COVID-19 pandemic, utilizing a semi-structured interview guide developed by the research team, as it relates to their receipt of health care, experiences as a pregnant person and new parent, and the role of patient navigation in this time periodMeasure: Pregnancy/postpartum experiences during the pandemic Time: At any point during the COVID-19 pandemic, up to 3 months after the end of the pandemic
Description: Qualitative feedback on how NNM2 can meet the needs of the clinicians and optimize the transition to primary care, as assessed by feedback from obstetrician and primary care provider focus groupsMeasure: Evaluate clinician perspectives on patient navigation Time: Through completion of study, an average of 3 years
Description: Number of clinicians who believed NNM2 met their needs and improved patient care, as determined by surveys feedbackMeasure: Evaluate clinician experiences with NNM2 Time: Through completion of study, an average of 5 years
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports